Flaws Could Have Exposed Cryptocurrency Exchanges to Hackers – WIRED

Most people use either an app, an online platform, or a small hardware device as a wallet to store their cryptocurrency safely. The exchanges through which cryptocurrency changes hands, though, and other high stakes operations need something more like a massive digital bank vault. At the Black Hat security conference on Thursday, researchers detailed potential weaknesses in these specially secured wallet schemes, including some that affected real exchanges that have now been fixed.

The attacks aren't the digital equivalent of jackhammering a weak point on a safe or blowing up a lock. They're more like opening an old-timey bank vault with six keys that all have to turn at the same time. Breaking cryptocurrency private keys into smaller chunks similarly means an attacker has to cobble them together first to steal funds. But unlike distributing physical keys, the cryptographic mechanisms that underly multiparty key management are complex and difficult to implement correctly. Mistakes could be costly.

"These organizations are managing a lot of money, so they have quite high privacy and security requirements," says Jean-Philippe Aumasson, cofounder of the cryptocurrency exchange technology firm Taurus Group and vice president at Kudelski Security. "They need a way to split the cryptocurrency private keys into different components, different shares, so no party ever knows the full key and there isn't a single point of failure. But we found some flaws in how these schemes are set up that are not just theoretical. They could really have been carried out by a malicious party."

For the work, Aumasson, a cryptographer, validated and refined vulnerability discoveries made by Omer Shlomovits, cofounder of the mobile wallet maker ZenGo. The findings break down into three categories of attacks.

The first would require an insider at a cryptocurrency exchange or other financial institution exploiting a vulnerability in an open-source library produced by a prominent cryptocurrency exchange that the researchers declined to name. The attack takes advantage of a flaw in the library's mechanism for refreshing, or rotating, keys. In distributed key schemes, you don't want the secret key or its components to stay the same forever, because over time an attacker could slowly compromise each part and eventually reassemble it. But in the vulnerable library, the refresh mechanism allowed one of the key holders to initiate a refresh and then manipulate the process so some components of the key actually changed and others stayed the same. While you couldn't merge chunks of an old and new key, an attacker could essentially cause a denial of service, permanently locking the exchange out of its own funds.

Most distributed key schemes are set up so only a predetermined majority of the chunks of a key need to be present to authorize transactions. That way the key isn't lost entirely if one portion is accidentally eliminated or destroyed. The researchers point out that an attacker could use this fact to extort money from a target, letting enough portions of the key refreshincluding the one they controlthat they can contribute their portion and restore access only if the victim pays a price.

The researchers disclosed the flaw to the library developer a week after the code went live, so it's unlikely that any exchanges had time to incorporate the library into their systems. But because it was in an open-source library, it could have found its way into numerous financial institutions.

In the second scenario, an attacker would focus on the relationship between an exchange and its customers. Another flaw in the key rotation process, in which it fails to validate all of the statements the two parties make to each other, could allow an exchange with malicious motivations to slowly extract the private keys of its users over multiple key refreshes. From there a rogue exchange could initiate transactions to steal cryptocurrency from its customers. This could also be carried out quietly by an attacker who first compromises an exchange. The flaw is another open-source library, this time from an unnamed key management firm. The firm does not use the library in its own offerings, but the vulnerability could have been incorporated elsewhere.

Read the rest here:

Flaws Could Have Exposed Cryptocurrency Exchanges to Hackers - WIRED

Cryptocurrency Cards: An Unnecessary Solution That Should Be Stopped – Cointelegraph

Crypto cards have become a must-have for many crypto services. Hoping to reduce the risk of blocking transactions, companies have been looking again and again for reason why their customers should use plastic. But a crypto card is a placebo that does not solve the problems of either users or fintech companies its only goal is to bring profit to payment systems and intermediaries.

Crypto cards are not needed in the same way that special financial instruments are not needed to buy gold, oil, precious metals or any other resource. The word cryptocurrency like dollar or euro indicates only the currency for transactions with which the card can be used and does not make the banking product any more innovative. However, until banks and payment systems recognize this, we will be forced to eliminate the consequences of cooperation with Wirecard, WaveCrest and other processors that arent the most conscientious, wanting to make money by taking risks but without being able to manage them.

Bank card technologies have gone through a rapid evolutionary path in a very short period of time. They are the fundamental and connecting element for all retail trade relationships. According to Nilson Report, there are currently more than 22 billion payment cards in circulation around the world debit, credit and prepaid. Taking into account that 1.7 billion people do not use banking services at all, for each of the remaining 6 billion people, there are on average 3.6 cards.

All cards are serviced by payment systems that create a closed consumption ecosystem. Heres what happens:

Banks and processor companies pay Visa, Mastercard, UnionPay, American Express and other international payment systems for the possibility of issuing cards.

Cardholders pay banks an annual fee or transaction fees.

Sellers transfer to banks on average 1%4% of the transaction amount for acquiring servicing.

Various intermediaries, aggregators, API providers, etc. also collect a commission.

The main thing is that in each commission payment between all participants, a share of Visa, Mastercard or another payment system is included. If we are talking about cryptocurrency transactions, then the commission of payment systems will be higher, since the traditional financial industry regards these transactions as high-risk.

And yet, bank cards are almost indispensable for transactions worth up to $5,000. This is the fastest and most convenient way to buy crypto from numerous wallets and/or exchanges. Therefore, it would be naive to think that fintech companies could quickly get rid of the intermediation of payment systems and stop paying them for every transaction.

Nevertheless, Visa and Mastercard can do a lot to make their native cards much friendlier to crypto and become a part of the solution, not part of the problem, which Wirecard has been trying to get around, making this kind of change seem inevitable.

Today, when the volume of non-cash payments in many countries has surpassed cash payments, any company wanting to issue bank cards under its own brand, in theory, has three options.

1. Become a principal (direct) participant in the international system. To do this, you need to meet a number of mandatory criteria: have the necessary technological platform and qualified personnel, meet information security requirements, provide security funds, etc.

For example, last year, a principal Visa participant had to have capital of at least $56 million directly with the Visa payment system. Therefore, you need to have an account in United States dollars in the U.S. or in euro in the European Union. The licensing procedure itself can cost about $1 million, excluding the funds required for the security deposit and direct royalties. This is not a realistic option for small and medium fintech companies.

2. Become an associated member of the payment system through the sponsoring bank. In this case, it is the bank that takes care of the compliance with the payment system requirements. The license fee is $200,000$300,000, plus a deposit of several million dollars.

However, even under such conditions, financial organizations do not want to directly cooperate with crypto companies since transactions with cryptocurrency are classified by payment systems as high-risk due to the lack of a unified approach to regulating this area. This results in higher fees and chargebacks for transactions that have been challenged by the cardholder.

3. Contact a processing company. Unlike banks, processors are responsible for issuing payment cards. Among such processors, crypto services usually find partners with a high-risk appetite that are willing to cooperate. Such companies are ready to use various tricks so that payments passing through them are not blocked by the payment system. For example:

Conceal or falsify before the payment system the main activity of the company for which the issue occurs.

Use incorrect Merchant Category Codes.

Issue crypto cards on their own Bank Identification Number, while according to the rules of payment systems, a separate BIN must be allocated for each individual product.

Issue co-branded cryptocurrency cards, which are, in fact, bank cards with an individual design and are then sold through a crypto service.

Expand the limits of card transactions, regardless of the requirements of payment systems and/or the regulator, etc.

All of these are often unjustified risks that processors like Wirecard take on, increasing the cost of issuing and maintaining crypto cards for both crypto services and end-users. Meanwhile, the value of these crypto cards continues to depreciate.

Until recently, people were forced to buy a fourth or even fifth payment card, only for the sake of the crypto prefix in order to save their money from being blocked during operations with cryptocurrency. However, regulated crypto services have already learned to tackle this problem differently by acting strictly within the framework of compliance requirements and forging links with traditional financial institutions.

High-risk processors like Wirecard or Wavecrest can be compared to microfinance institutions, or MFIs, that lend out at huge interest rates. Usually, people turn to MFIs after numerous and not always objective refusals by banks to issue a loan. Sometimes, the money is needed urgently, and the consideration of the application in the bank is delayed; sometimes the banks scoring system does not like the place of work, marital status or the gender of a person. There may be many reasons, but the result is the same: The bank does not want to take risks and people go to less discerning financial intermediaries. Crypto services are forced to do this, too.

A cryptocurrency card is a ridiculous, temporary and forced necessity because banks and payment systems do not want to manage risks on their own. All the risks that Wirecard once assumed when working with crypto companies are now easily eliminated.

Licensing of activities in the field of cryptocurrencies, the implementation of KYC/AML procedures, obtaining a compliance certificate of the payment card industry data security standards and other measures allow crypto services to successfully work with the traditional financial system.

Banks should have the courage to start making money by partnering with regulated crypto services. And for this, above all else, it is necessary to develop internal expertise in the field of compliance. As bank employees have had little motivation to deal with the peculiarities of high-risk transactions, it is easier for them to refuse service to potential clients and/or stop transactions.

However, if a banks compliance service monitors and skips high-risk transactions on a regular and systematic basis, this will create additional cash flow, from which banks could also receive commissions. I am sure that cryptocurrency users right to dispose of honestly received assets should be ensured in an absolutely transparent, legal way, and not by gray schemes. Any card can be crypto, and this is the reality we should all be living in sooner rather than later.

The views, thoughts and opinions expressed here are the authors alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Alex Axelrod is the founder and CEO of Aximetria and Pay Reverse. He is also a serial entrepreneur with over a decade of experience in leading world-class technological roles within a large, number-one national mobile operator and leading financial organizations. Prior to these roles, he was the director of big data at the research and development center of JSFC AFK Systems.

Excerpt from:

Cryptocurrency Cards: An Unnecessary Solution That Should Be Stopped - Cointelegraph

Cryptocurrency This Week: India Could Ban Virtual Currencies & More – Inc42 Media

The Indian government is reportedly having inter-ministerial consultations on a proposed bill to ban all types of cryptocurrencies

Ripple CEO says there is an erosion of trust in global financial markets

Chinas central bank is planning to use its digital currency to challenge the dominance of Alipay and WeChat pay

Trouble may be looming on the horizon for cryptocurrency trading platforms in India, with the government reportedly moving into advanced deliberations over a bill from last year which seeks a complete ban on virtual currencies.

The bill, entitled, Banning of Cryptocurrency and Regulation of Official Digital Currency Bill, 2019, was drafted by an inter-ministerial committee headed by former Finance and Department of Economic Affairs (DEA) Secretary Subhash Chandra Garg. Lawyer Mohammed Danish, the co-founder of Crypto Kanoon, a crypto regulatory media platform, had filed an RTI application with the Department of Economic Affairs to establish whether media reports suggesting that the government had begun consultations on the bill were accurate.

In his RTI, Danish had inquired, Has any cabinet note been sent for IMC (inter-ministerial consultation) on the legal framework of cryptocurrencies/virtual currencies? and, Does this cabinet note seek inter-ministerial consultation on Banning of Cryptocurrency & Regulation of Official Digital Currency Bill, 2019? If not, what is the purpose of this cabinet note?

In its reply to Danishs RTI, the Department of Economic Affairs wrote, The government had set up an inter-ministerial committee (IMC) for examining the issue of cryptocurrencies. The report of the IMC on VCs (virtual currencies) has since been submitted by its members but is awaiting approval of the government. The report and bill will now be examined by the government through inter-ministerial consultation by moving a cabinet note in due course.

The proposed bill calls for a complete ban on all cryptocurrencies and related activities such as mining, holding, advertising, promoting, buying, selling and providing exchange services, among other things. Indian institutions have long been hostile towards cryptocurrencies as it is believed that such currencies are used for anti-social purposes such as funding terrorist activities, a fact backed through evidence collected by the Financial Action Task Force (FATF), an inter-governmental organisation to combat money laundering. These supposed ramifications are believed to be a consequence of cryptocurrencies being outside the purview of any countrys central bank, the lack of any underlying fiat, episodes of excessive volatility in their value, and their anonymous nature which goes against global money-laundering rules.

In March this year, the Supreme Court quashed a Reserve Bank of India (RBI) circular from 2018 which had ordered a banking ban on cryptocurrencies in India. Since the SC order, there has been a spurt in cryptocurrency-related activities in India, with some crypto exchange platforms reporting a 400% spike in trading activity. It remains to be seen if the positive outlook for cryptocurrency exchange platforms in India will hit a roadblock with the coming of a blanket ban on virtual currencies possibly in the upcoming monsoon session of the Indian Parliament, the dates for which are yet to be notified

In other news, Bitcoin is trading at $11,135 at the time of writing, reporting a marginal increase of 1.69% from last week, when the price of a Bitcoin was $10,949. Bitcoins market cap is $205.46 Bn.

Ethereum is trading at $391.52, reporting an increase of around 24% from last week, when the price of Ethereum was $316.6. Ethereums market cap is $43.86 Bn.

Brad Garlinghouse, CEO of global payments system Ripple, has said that in an uncertain world where the global economy is witnessing a downturn due to the financial disruption caused by the Covid-19 pandemic, governments were seriously considering the blockchain technology. Garlinghouse, in a series of tweets, while commenting on a Bloomberg article which detailed the pros and cons of potential alternatives to the dollar such as gold, yuan and crypto, said that with the erosion of trust in the global financial system, people will inevitably gravitate towards cryptocurrencies. It addresses frictions (settlement, transparency, among others) that were assumed VERY hard to solve before. Crypto is up 80% while USD is down 3% YTD, Garlinghouse wrote in a tweet.

Garlinghouse admitted that the US dollars dominance as the backbone of the global financial infrastructure wasnt going to be lost anytime soon to other assets such as gold, the yuan or crypto, among others, anytime soon. But is it weaker today? he asked. Evidently, as the dollar index, which measures the greenback against a host of leading currencies, had its worst month in a decade in July, as it lost more than 4%. It is down 10% from its peak in March.

Chinas central bank, the Peoples Bank of China (PBoC), is reportedly planning to use its digital currency electronics system to counter the dominance of Chinese tech giants Alibaba and Tencent in the countrys digital payments sector. The report comes only a few days after it was reported that PBoC had promoted an antitrust investigation against both companies digital payments platforms, Alipay and WeChat Pay for suppressing competition in the sector. PBoC will use the DCEP to provide banks equal opportunities in the field of digital payments as it earlier did to technology giants.

Read the rest here:

Cryptocurrency This Week: India Could Ban Virtual Currencies & More - Inc42 Media

US Congressmen Want IRS to Balance Taxation and Innovation in the Cryptocurrency Space | Taxes – Bitcoin News

A bipartisan quartet of US congressmen wants the IRS taxation policy not to dissuade taxpayers from participating in blockchain token staking.

These politicians believe Americas ingenuity can help drive this promising staking technology.

The four congressmen are Bill Foster (D) of Illinois, Darren Soto (D) of Florida, Tom Emmer (R) of Minnesota, and David Schweikert (R) of Arizona.

In their letter addressed to IRS Commissioner Charles Rettig, the quartet expressed concern that the taxation of staking rewards as income may overstate taxpayers actual gains from participating in this new technology.

They add this could result in a reporting and compliance nightmare, for taxpayers and the Service alike.

The letter, in which the U.S. politicians explain their understanding of proof-of-stake (POS), also gives reasons why they favor POS ahead of bitcoins proof-of-work consensus.

The politicians say in addition to needing massive amounts of energy, the Bitcoin network is secured by a relatively small number of miners. On the other hand, in POS, all tokenholders can contribute to network security.

By staking tokens, participating third-party tokenholders can also receive newly created tokens as rewards for helping to maintain the network.

The quartet says it agrees with the principle that taxpayers true gains from these tokens should indeed be taxed.

However, the politicians suggest a different solution:

Similar to all other forms of taxpayer-created (taxpayer-discovered) property such as crops, minerals, livestock, artwork, and even widgets off the assembly line these tokens could be taxed when they are sold.

Eager to keep the U.S. abreast with this technology, the congressmen end their letter by urging the IRS to continue pursuing its mandate but also (to) ensure innovation wont be driven elsewhere.

This letter by the four members of Congress is the latest signal that the U.S. is moving to embrace blockchain technology and cryptocurrencies.

In July, the Office of the Comptroller of the Currency (OCC) clarified that national banks and federal savings associations can provide cryptocurrency custody services for customers.

Also in the same month, a U.S. federal court ruled that bitcoin is a form of money.

Meanwhile, reacting to the letter by the U.S. congressmen, Tim Ismilyaev, CEO and founder at Mana Security, says the growth of POS has finally forced some people in the U.S. government to see the importance of embracing cryptocurrencies.

The US government recognizes the immense growth of assets locked in POS and defi [decentralized finance] markets (over $15B is already locked in such products) although these markets did not exist a few years ago. The value of locked assets is likely to surpass $100B mark in upcoming years, and this will happen with or without US approval. So this move by Congress toward crypto is rational.

The bipartisan letter was written on July 29.

What do you think of this letter? Tell us your thoughts in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons

See the original post:

US Congressmen Want IRS to Balance Taxation and Innovation in the Cryptocurrency Space | Taxes - Bitcoin News

Cryptocurrency Market Update: Bitcoin flirts with $12,000, Cosmos and Band Protocol lead the altcoin rally – FXStreet

Bitcoin is leading the market with considerable gains on Monday following a weekend characterized by stability at $11,500. The impressive price action pushed BTC above $12,000 but stalled short of $12,100. An intraday high was traded at $12,083 cut shot the momentum resulting in a reversal below $12,000. At the time of writing, Bitcoin is pivotal at $12,000, although buyers lack the energy to keep the price above this same level.

The daily chart shows that consolidation is likely to take precedence in the short term. The RSI is currently horizontal at 70 (significantly lower than the levels seen during the last week of July and the first week of August). The MACD also highlights a sideways price action. If this consolidation would be a stepping stone for gains above $13,000, it is something that we will have to wait to see. For now, establishing higher support seems to be the wisest action to make.

Read more:Cryptocurrency Market News: Bitcoin attacks $12,000 as selected altcoins roar

Cosmos is among the best performing cryptocurrencies in the market. In the last 24 hours, this token has surged over 20% to trade highs of $5.88 from the lowest level traded in August at $3.50. As reported during the Asian hours, ATOM is holding well in the hands of the bulls despite the minor correction to $5.64 (prevailing market value).

The price also extended the action above the moving averages with the 50 SMA and 200 SMA holding positions at $4.78 and $4.22. Other key support areas include $5.50, $5.00 and $4.00. ATOM/USD 1-hour chart.

Read more:Cosmos Price Forecast: ATOM/USD goes ballistic eyeing $6.00 critical level

Band Protocol price update

BAND/USD is flying the bullish flag pattern high in the skies following gains of over 34% in the last 24 hours. After starting the month of August trading around $4.21, Band Protocol has more than quadrupled its value trading highs of $18.00. At the time of writing, the digital currency is trading at $15.51 following a minor retreat. The token is still in the bulls hands with gains towards $20.00 still possible in the near term.

Continued here:

Cryptocurrency Market Update: Bitcoin flirts with $12,000, Cosmos and Band Protocol lead the altcoin rally - FXStreet

Will This Quantum Computing Breakthrough Save Bitcoin and Cryptocurrency? – The Daily Hodl

A new computing breakthrough may just save Bitcoin and cryptocurrency from powerful quantum machines that have the potential to breach public-key cryptography.

Researchers are following the development of a new measure known as lattice-based cryptography that promises to make crypto technology more quantum-proof, reports MIT Technology Review.

Lattice-based cryptography may neutralize the massive computational capabilities of quantum computers by hiding data inside complex geometric structures that contain a grid of infinite dots that are spread across thousands of dimensions. The security measure appears to be virtually impenetrable even with the use of powerful quantum computers unless one holds the key.

The emergence of quantum computing machines has grabbed headlines over the past few months as the technology poses a threat to cryptographic algorithms that keep cryptocurrencies, like Bitcoin as well as the internet at large secure. The World Economic Forum explains how quantum computers can break current standards of encryption.

The sheer calculating ability of a sufficiently powerful and error-corrected quantum computer means that public-key cryptography is destined to fail, and would put the technology used to protect many of todays fundamental digital systems and activities at risk.

MIT Technology Review says that while the current iterations are not yet ready for implementation, the solution is promising, especially as a post-quantum future is fast approaching. Ripple CTO David Schwartz says he believes developers have at least eight years until the technology, which leverages the properties of quantum physics to perform fast calculations, becomes sophisticated enough to crack cryptocurrency.

I think we have at least eight years. I have very high confidence that its at least a decade before quantum computing presents a threat, but you never know when there could be a breakthrough. Im a cautious and concerned observer, I would say.

Featured Image: Shutterstock/archy13

Visit link:

Will This Quantum Computing Breakthrough Save Bitcoin and Cryptocurrency? - The Daily Hodl

Hulk Just Exploded Into Bits and Pieces in The Immortal Hulk #35 – Screen Rant

Hulk just overloaded with green energy and exploded in The Immortal Hulk #35. Is the 'Immortal Hulk' more mortal than readers have believed?

Warning! Spoilers for Immortal Hulk #35 below

The Hulk is known for his body's extreme resilience. His body is so durable because of his ability to increase his strength through anger. Hulk is so close to immortal that he is often pitted against Marvel's strongest heroes and villains. Hulk has survivedcountless destructive events and deadly foes, but in The Immortal Hulk #35,his body was just completely obliterated by an explosion from within.

The Hulk is a hero so powerful that some of his fellow heroes once tricked him into leaving the earth because of his capacity for destruction. While he appears immortal (and become seemingly immortal in the current run) he has momentarily died in several comics only to be saved or revived by a miraculous event. His death in The Immortal Hulk #35was one of the most complete and brutal because his entire body was reduced to shreds of skin and bone in the final panel.

Related:Hulk's Strong Enough To Wear TWO Infinity Gauntlets (in Comics)

The Immortal Hulk #35by Al Ewing, Mike Hawthorne, Mark Morales, Paul Mounts, Cory Petit, and Alex Ross ends with Bruce Banner's body left in tatters after he internally combusts. This issue finds Hulk helping build a house as part of his quest to do good and control his extreme emotions. His actions turn into a big press scene for the local mayor. Little does Bruce know, one of his greatest foes, The Leader is mere feet away from him, disguised as Bruce's close friend Rick Jones. Just as Hulk calms himself down from a close call with losing his temper, The Leader strolls up to him in Rick's body and lays a hand on his shoulder. The Leader charges Hulk's body with a green light that might be gamma radiation.

The green light energy fills The Hulk's body first escaping his eyes and mouth until it eventually explodes obliterating Hulk's body and killing two bystanders. The Leader is one of the most capable Hulk villains due to the superintelligence at his disposal. He, like The Hulk, was a product of gamma radiation. Fans have seen Hulk's body endure all kinds of punishment including getting his neck snapped in comics or his body scorched in Avengers: Endgame.Despite getting extremely close to dying many times, Hulk has rarely had his entire body destroyed such as in The Immortal Hulk #35.

The Leader has historically been one of The Hulk's fiercest opponents in the comics so has he finally done what seemed impossible? It is difficult to fathom what writer Al Ewing has in store for Marvel's big green powerhouse. This suspenseful story poses a question that Hulk fans have been pondering since his inception. Is the 'Immortal Hulk' truly immortal?

Next:How Powerful The Hulk Really Is In Each MCU Movie

Source: The Immortal Hulk #35

Star Wars: The REAL Reason Luke Escaped Darth Vader

Charles Singh is a reader, writer, and huge geek. He is based in The Bronx, New York. He received a Bachelor of Arts degree in English literature in 2019 from Lehman College. He has worked for several non-profit organizations including The Harlem Children's Zone, MMCC, and The GO Project, assisting New York City's youth and spreading a love for literature.

See the article here:

Hulk Just Exploded Into Bits and Pieces in The Immortal Hulk #35 - Screen Rant

First Amendment Protections in K-12 Schools Not "Restricted to Only Core Political Speech" – Reason

So holds the First Circuit in yesterday's decision in Norris v. Cape Elizabeth School Dist., and I think that's exactly the right reading of the Supreme Court precedents (and consistent with other circuits' decisions).

The particular speech in that case was an anonymous "sticky note on a mirror in a Cape Elizabeth High School girls' bathroom that stated 'THERE'S A RAPIST IN OUR SCHOOL AND YOU KNOW WHO IT IS.'" One might argue that this is core political speech, because it's an implicit accusation that the school isn't doing anything about this, but the court's decision makes it unnecessary to draw the political/nonpolitical line. "Because we conclude that Tinker is not limited to political speech, we need not decide if A.M.'s sticky note, understood in the context of her prior activities related to sexual assault activism including her statements to the Cape Elizabeth H.S. school board, was objectively viewed as political."

Read more:

First Amendment Protections in K-12 Schools Not "Restricted to Only Core Political Speech" - Reason

Nootropics Market Report to 2026 Industry Demand Analysis and Current Trend – Bulletin Line

Nootropics Market Industry Forecast To 2026

Garner Insights has titled a new research report named as Nootropics Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate. It consolidates all the fundamental factors that are foreseen to change inside the market. The information would thus be used to heighten an organizations standing in the worldwide market.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak.

Get a Sample Report @:https://www.garnerinsights.com/Covid-19-Impact-on-Global-Nootropics-Market-Insights-Forecast-to-2026#request-sample

Major Manufacturer Detail:Nootrobox, Cephalon, Purelife Bioscience, Peak Nootropics, Nootrico, SupNootropic Biological Technology, AlternaScript, Accelerated Intelligence, Onnit Labs, Powder City, Ceretropic, Nootropic Source, Clarity Nootropics

The Important Type Coverage:Attention and Focus, Memory Enhancement, Mood and Depression, Sleep and Anxiety, Others

Segment by ApplicationsAdult, Kid

The Nootropics report consists of streamlined financial data obtained from various research sources to provide specific and trustworthy analysis. Evaluation of the key market trends with a positive impact on the market over the following couple of years, including an in-depth analysis of the market segmentation, comprising of sub-markets, on a regional and global basis. The report also provides a detailed outlook of the Nootropics market share along with strategic recommendations, on the basis of emerging segments.

Enquire Here For Discount Or Report @https://www.garnerinsights.com/Covid-19-Impact-on-Global-Nootropics-Market-Insights-Forecast-to-2026#discount

Some Of The Major Geographies Included In This Study:

North America (U.S and Canada and Rest of North America)Europe (Germany, France, Italy and Rest of Europe)Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Some major points covered in this Nootropics Market report:

1. An overall outlook of the market that helps in picking up essential data.2. The market has been segmented on the basis of the product types, applications, end-users, as well as the industry verticals, in light of numerous factors. Considering the market segmentation, further analysis has been carried out in an effective manner. For better understanding and a thorough analysis of the market, the key segments have further been partitioned into sub-segments.3. In the next section, factors responsible for the growth of the market have been included. This data has been collected from the primary and secondary sources and has been approved by the industry specialists. It helps in understanding the key market segments and their future trends.4. The report also includes the study of the latest developments and the profiles of major industry players.5. The Nootropics market research report also presents an eight-year forecast on the basis of how the market is predicted to grow.

View Full Report @ https://garnerinsights.com/Covid-19-Impact-on-Global-Nootropics-Market-Insights-Forecast-to-2026

About Us:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry.Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: [emailprotected]

Here is the original post:

Nootropics Market Report to 2026 Industry Demand Analysis and Current Trend - Bulletin Line

In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Canine Stem Cell Therapy Coronavirus Impact Editon of Key Players VETSTEM…

Rising number of corona virus cases has impacted numerous lives and led to numerous fatalities, and has affected the overall economic structure globally. The Canine Stem Cell Therapy has analyzed and published the latest report on the global Canine Stem Cell Therapy market. Change in the market has affected the global platform. Along with the Canine Stem Cell Therapy market, numerous other markets are also facing similar situations. This has led to the downfall of numerous businesses, because of the widespread increase of the number of cases across the globe.href=mailto:nicolas.shaw@cognitivemarketresearch.com>nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Request Free Sample Copy of Canine Stem Cell Therapy Market Research Report@ https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

The major players in the Canine Stem Cell Therapy market are VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet . Some of the players have adopted new strategies to sustain their position in the Canine Stem Cell Therapy market. A detailed research study is done on the each of the segments, and is provided in Canine Stem Cell Therapy market report. Based on the performance of the Canine Stem Cell Therapy market in various regions, a detailed study of the Canine Stem Cell Therapy market is also analyzed and covered in the study.

Report Scope:Some of the key types analyzed in this report are as follows: Allogeneic Stem Cells, Autologous Stem cells

Some of the key applications as follow: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Following are the major key players: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

An in-depth analysis of the Canine Stem Cell Therapy market is covered and included in the research study. The study covers an updated and a detailed analysis of the Canine Stem Cell Therapy market. It also provides the statistical information of the Canine Stem Cell Therapy market. The study of the report consists of the detailed definition of the market or the overview of the Canine Stem Cell Therapy market. Furthermore, it also provides detailed information for the target audience dealing with or operating in this market is explained in the next section of the report.

Read Detailed Index of full Research Study @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

The report also provides detailed information on the research methodologies, which are used for the analysis of the Canine Stem Cell Therapy market. The methods are covered in detail in this section of the report. For the analysis of the market, several tools are used for the extraction of the market numbers. Among the several tools, primary and secondary research studies were also incorporated for the research study. These were further analyzed and validated by the market experts, to increase precision and make the data more reliable.

Moreover, the report also highlights and provides a detailed analysis of the drivers, restrains, opportunities, and challenges of the Canine Stem Cell Therapy market. This section of Canine Stem Cell Therapy market also covers the updated information, in accordance with the present situation of the market.

According to the estimation and the analysis of the market, the Canine Stem Cell Therapy market is likely to have some major changes in the estimated forecasts period. Moreover, these changes can be attributed to the changes due to economic and trading conditions across the globe. Moreover, several market players operating in the Canine Stem Cell Therapy market will have to strategically change their business strategies in order to survive in the market.

If Any Inquiry of Canine Stem Cell Therapy Report @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

Reasons for Buying this Canine Stem Cell Therapy Report1. Canine Stem Cell Therapy market advertise report helps with understanding the Basic product segments alongside likewise their potential future.2. This global Canine Stem Cell Therapy report offers pin-point evaluation for changing competitive dynamics.3. The Canine Stem Cell Therapy market supplies pin point analysis of changing competition dynamics and keeps you in front of competitors4. Original images and illustrated a SWOT evaluation of large segments supplied by the Canine Stem Cell Therapy market.5. This report supplies a forward-looking perspective on different driving factors or controlling Canine Stem Cell Therapy market gain.6. This report assists to make wise business choices using whole insights of the Canine Stem Cell Therapy and also from creating a comprehensive evaluation of market sections.Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

*If you have any special requirements, please let us know and we will offer you the report as you want Click Here>Download Customized Sample Report of Canine Stem Cell Therapy Market Report 2020 (COVID-19 Impact Analysis Updated Edition May 2020)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.

Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

Excerpt from:

In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Canine Stem Cell Therapy Coronavirus Impact Editon of Key Players VETSTEM...

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of…

METUCHEN, N.J., Aug. 10, 2020 /PRNewswire/ --Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expertNeal Flomenberg, M.D., Professor and Chair of the Department of Medical Oncology at Thomas Jefferson University, with the intent to evaluate Tevogen' s proprietary antigen-specific T cell technology as a potential treatment for COVID-19 and influenza-A patients.

This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise and research prowess to investigate potential treatments for viral infections.

Dr. Flomenberg has been at the forefront of immunogenetics and immunology for more than four decades. "Tevogen's technology resonated with me as there have been several groups who have used T cells to treat patients after bone-marrow transplants. The idea of utilizing T cell therapies to potentially treat COVID-19 and other viruses is truly remarkable," Flomenberg said. "I'm enthusiastic about moving forward with an investigation of Tevogen's technologies."

Tevogen CEO Ryan Saadi, M.D., M.P.H., is leading the new biotech's efforts. "Our work has been to pioneer T cell therapies that can be abundantly and efficiently reproduced to develop an affordable and scalable cellular treatment for the biggest global health threats, including COVID-19, influenza, and a variety of cancers. We are very excited about Dr. Flomenberg's contribution to our efforts and hope to initiate our investigational study soon."

In addition to developing its potential therapies, Tevogen is committed to organizational and manufacturing efficiency. This should allow it to engage in affordable innovation to the benefit of all patients.

About Tevogen Bio

Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the health care industry, to help address some of the most common and deadly illnesses known today. The company's mission is to provide curative and preventative treatments that are affordable and scalablein order to positively impact global public health.

About Dr. Neal Flomenberg

Dr. Neal Flomenberg is the Chairman of Medical Oncology at Jefferson University in Philadelphia and also heads the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Program. Throughout his more than four decades of practice, he has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. Dr. Flomenberg developed an approach to bone-marrow transplants that uses half-matched relatives as donors, a breakthrough that assures that the majority of blood and bone-marrow cancer patients can benefit from this potentially curative treatment.

Media Contacts:

Mark Irion[emailprotected]

Katelyn Petroka [emailprotected]

SOURCE Tevogen Bio

Read the original post:

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of...

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results – PRNewswire

HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

"We continue to make progress toward advancing our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia, or AML," said Peter L. Hoang, President & CEO of Marker Therapeutics. "While the COVID-19 pandemic has impacted hospital systems globally, we have augmented our process development for our MT-401 product, continued the buildout of our manufacturing facility and added further clinical sites for our Phase 2 AML trial. With a novel cell therapy product candidate that has demonstrated the ability to induce broad and durable immune responses in earlier clinical studies, Marker remains well-positioned to provide a potential treatment option for patients suffering from this devastating disease."

PROGRAM UPDATES

Multi-Antigen Targeted (MultiTAA) T Cell Therapies

Phase 2 AML Trial Update The Company continues to identify and add clinical trial sites in preparation for the Phase 2 AML trial initiation. The study is currently subject to a partial clinical hold on the use of a new reagent in the manufacturing processuntil the FDA reviews and accepts the final data and certificates of analysis for the new reagent. The alternate supplier has been delayed in providing the reagent but expects to ship the reagent to Marker in Q3. Once Marker receives the reagent and completes the required analyses for FDA, the Company will provide additional clarification around the timing of the AML trial enrollment.

USAN Council Approval of "Zelenoleucel" for MT-401Marker recently announced that the United States Adopted Names (USAN) Council approved "zelenoleucel" as the nonproprietary (generic) name for MT-401, a MultiTAA-specific T cell product candidate for the treatment of patients with AML following allogeneic stem cell transplant in both adjuvant and active disease settings.

Pancreatic Cancer Data Presented During ASCO Updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the Company's MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma, were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. Data from a cohort of patients receiving MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapy in the first-line setting (Arm A) were presented.

BUSINESS UPDATES

On June 30, 2020, Marker announced that the Company executed a lease agreement to establish an in-house cGMP manufacturing facility in Houston, TX. The facility is expected to be completed by year-end and operational in 2021. Marker will continue to manufacture its MultiTAA-specific T cell therapy at the Baylor College of Medicine to support the Company-sponsored AML trial until the in-house cGMP manufacturing facility is operational.

SECOND QUARTER 2020 FINANCIAL RESULTS

Cash Position and Guidance:At June 30, 2020, Marker had cash and cash equivalents of $32.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into Q2 2021.

R&D Expenses:Research and development expenses were$4.3 million for the quarter endedJune 30, 2020, compared to$3.2 million for the quarter ended June 30, 2019.

G&A Expenses:General and administrative expenses were$2.5 million for the quarter endedJune 30, 2020, compared to $2.7 million for the quarter ended June 30, 2019.

Net Loss:Marker reported a net loss of$6.3 millionfor the quarter endedJune 30, 2020, compared to a net loss of$5.6 million for the quarter ended June 30, 2019.

About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; and the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.Condensed Consolidated Balance Sheets

June 30,

December 31,

2020

2019

(Unaudited)

(Audited)

ASSETS

Current assets:

Cash and cash equivalents

$ 32,124,187

$ 43,903,949

Prepaid expenses and deposits

2,632,514

1,526,442

Interest receivable

3,440

56,189

Total current assets

34,760,141

45,486,580

Non-current assets:

Property, plant and equipment, net

1,592,094

417,528

Construction in progress

2,629,141

-

Right-of-use assets, net

9,542,228

455,174

Total non-current assets

13,763,463

872,702

Total assets

$ 48,523,604

$ 46,359,282

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$ 4,528,021

$ 1,757,680

Lease liability

456,065

204,132

Warrant liability

-

31,000

Total current liabilities

4,984,086

1,992,812

Non-current liabilities:

Lease liability, net of current portion

9,025,273

280,247

Total non-current liabilities

9,025,273

280,247

Total liabilities

14,009,359

2,273,059

Commitments and contingencies

-

-

Stockholders' equity:

Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively

-

-

Common stock, $0.001 par value, 150 million shares authorized, 46.6 million and 45.7 million shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively

46,617

45,728

Additional paid-in capital

374,828,385

371,573,909

Accumulated deficit

(340,360,757)

(327,533,414)

Total stockholders' equity

34,514,245

44,086,223

Total liabilities and stockholders' equity

$ 48,523,604

$ 46,359,282

See the article here:

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results - PRNewswire

University of Minnesota expands clinical investigation of engineered iPSC-derived natural killer cells, opening U.S. clinical trial for the treatment…

The first patient has received treatment in a new clinical trial that has opened at the University of Minnesota to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia (AML) and lymphoma can be effective as a treatment for COVID-19. The first-of-its-kind, engineered iPSC-derived natural killer (NK) cell product candidate, FT516, may play a role in diminishing viral replication of the novel coronavirus. NK cells have been known to play a role in protecting the body against viral infection; however, it is not known whether NK cells will be able to safely control COVID-19, the infectious disease caused by the virus SARS-CoV-2.

The clinical trial Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients with Hypoxia, which is being supported by Fate Therapeutics, Inc., is being run locally by Joshua Rhein, M.D., Assistant Professor of Medicine in the University of Minnesota Medical Schools Division of Infectious Diseases and International Medicine.

The medical research community has been mobilized to meet the unique challenges that COVID-19 presents, said Rhein. There are limited treatment options for COVID-19, and we have been inundated daily with reports of varying quality describing the potential of numerous therapies. We know that NK cells play an important role in responding to SARS-CoV-2, the virus responsible for COVID-19, and that these cells often become depleted in infected patients. Our intent is to replenish NK cells in order to restore a functional immune system and directly target the virus.

Jeffrey Miller, M.D., Deputy Director of the Masonic Cancer Center, and Professor of Medicine in the Medical Schools Division of Hematology, Oncology and Transplantation, is a pioneer in the field of NK cells. As a collaborator on the trial, Dr. Miller will apply his decades of experience in NK cell biology and therapy in cancer to this international challenge.

One of the complexities of treating COVID-19 with cell therapy is the underlying inflammation that coincides with more severe cases of COVID-19 infection. The challenge is to carefully deliver off-the-shelf engineered NK cells at increasing doses to turn off viral replication without overly activating the immune system to make the lungs worse.

The study has been carefully designed with appropriate medical checkpoints to investigate the potential of NK cells in a manner which we believe to be safe in COVID-19 patients, said Miller. We will also track the immune response and duration of viral shedding to see if FT516 decreases shedding of COVID-19 in the respiratory tract. If successful, these off-the-shelf, iPSC-derived NK cells can be batch manufactured and sent nationwide to patients.

FT516 is manufactured from a master human induced pluripotent stem cell (iPSC) line that has been genetically engineered to enhance its binding to therapeutic antibodies. It was initially developed to attack AML and B-cell lymphoma, based on the groundbreaking research on stem cells and NK cells done at the Masonic Cancer Center.

FT516, which is being clinically developed by Fate Therapeutics for the treatment of advanced hematologic malignancies and solid tumors, was produced and manufactured at the U of Ms Molecular and Cellular Therapeutics (MCT) center, which offers full-service development and manufacturing of cell- and tissue-based products, monoclonal antibodies and other therapeutic proteins, as well as active pharmaceutical ingredients for use in Phase I, II or III clinical trials. M Health Fairview, the clinical partner of the Masonic Cancer Center, supports the MCT in the production of these molecules.

###

Read the original release about FT516 here.

About the Masonic Cancer Center, University of MinnesotaThe Masonic Cancer Center, University of Minnesota, is the Twin Cities only Comprehensive Cancer Center, designated Outstanding by the National Cancer Institute. As Minnesotas Cancer Center, we have served the entire state for more than 25 years. Our researchers, educators, and care providers have worked to discover the causes, prevention, detection, and treatment of cancer and cancer-related diseases. Learn more at cancer.umn.edu.

About the University of Minnesota Medical SchoolThe University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Learn how the University of Minnesota is innovating all aspects of medicine by visiting http://www.med.umn.edu.

Read the rest here:

University of Minnesota expands clinical investigation of engineered iPSC-derived natural killer cells, opening U.S. clinical trial for the treatment...

Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19 – DocWire News

This article was originally published here

Front Med. 2020 Aug 6. doi: 10.1007/s11684-020-0810-9. Online ahead of print.

ABSTRACT

The Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O2 (FiO2) of the two patients gradually decreased while the oxygen saturation (SaO2) and partial pressure of oxygen (PO2) improved. Additionally, the patients chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS.

PMID:32761491 | DOI:10.1007/s11684-020-0810-9

Originally posted here:

Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19 - DocWire News

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – PharmiWeb.com

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C. August 6, 2020 The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented: The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is available online here, with key sector metrics and infographics available here. For more information, please visit http://www.alliancerm.org or contact Kaitlyn (Donaldson) Dupont at kdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Follow this link:

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - PharmiWeb.com

UPDATED: After a 4-year sojourn, struggling microbiome pioneer Seres claims a breakout PhIII comeback. And shares respond in frenzied spike -…

Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotechs future. Out front in their pursuit of a gut punch to C. difficile infection (CDI), the Phase II test was a flat failure, and investors wiped out a billion dollars of equity value that never returned in the years that followed.

Seres, though, pressed ahead, changing out CEOs a year ago bidding Merck vet Roger Pomerantz farewell from the C suite and pushing through a Phase III, hoping that amping up the dosage would make the key difference. And this morning, they unveiled a claim that they had aced the Phase III and positioned themselves for a run at a landmark FDA OK.

Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read more here:

UPDATED: After a 4-year sojourn, struggling microbiome pioneer Seres claims a breakout PhIII comeback. And shares respond in frenzied spike -...

Covid-19 roundup: CureVac beefs up its unicorn IPO dreams as billionaire owner takes this Covid-19 mRNA player on a forced march to Nasdaq; Kodak’s…

Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotechs future. Out front in their pursuit of a gut punch to C. difficile infection (CDI), the Phase II test was a flat failure, and investors wiped out a billion dollars of equity value that never returned in the years that followed.

Seres, though, pressed ahead, changing out CEOs a year ago bidding Merck vet Roger Pomerantz farewell from the C suite and pushing through a Phase III, hoping that amping up the dosage would make the key difference. And this morning, they unveiled a claim that they had aced the Phase III and positioned themselves for a run at a landmark FDA OK.

Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More:

Covid-19 roundup: CureVac beefs up its unicorn IPO dreams as billionaire owner takes this Covid-19 mRNA player on a forced march to Nasdaq; Kodak's...

Nearly 70K donated so far towards Wistaston boy’s 120K lifesaving treatment – Cheshire Live

A WIstaston family are overwhelmed by the generosity of people who have donated nearly 70K so far towards the 120K needed for lifesaving treatment for their 11-year-old son.

Georgy Capener was diagnosed with the highly malignant Ewings Sarcoma, a rare form of bone cancer, following a fall in a friends's garden on Easter Sunday in 2018.

He has undergone numerous rounds of high dose aggressive chemotherapy and radiotherapy since then, lost his right arm as a result of the treatment and now has a titanium prosthesis.

Georgy went into remission last March, but the cancer returned in April this year, this time in his left sinus, just under his eye socket and in the back of his nose.

The Wistaston Church Lane pupil is now undergoing chemotherapy and radiotherapy again - but the vital stem cell therapy which is essential to ensure he can live a normal, healthy life and prevent the cancer returning at a later stage costs 130,000 and is not available for Georgy on the NHS.

The money needs to be raised by the beginning of September, when Georgy is due to finish his final round of chemotherapy, as, for the stem cell treatment to be successful, the procedure would have to start immediately after that to ensure the cancer doesnt return straight away,

This week Georgys mum, Helen Capener, was close to tears she was so overwhelmed by the generosity of people who have donated and organised fundraisers.

I just cant believe the total raised so far, she said. Its just so nice. Weve got fundraisers doing things all over the place, my cousins biking from Peterborough to Crewe, weve got people in Cheadle doing stuff, everywhere, its brilliant

Ive been trying to keep up with whos donating. Its so lovely, Im still overwhelmed.

She said money had flooded in from Crewe Chronicle, CheshireLive and Liverpool Echo readers.

Passionate Liverpool fan Georgy has also received a video message of support from the Reds defender Andy Robertson.

It was brilliant, said Helen. Unfortunately I wasnt there when he received it. It was his dads turn to take him to radiotherapy so he saw it in the car so I didnt see his reaction but his dad said he was absolutely over the moon. His little face lit up and he just loves it. As soon as he came back, he ran in to show me.

There are so many fundraising events taking place to raise money for Georgys treatment, it is impossible to list them all here.

They range from an online fitness class which took place on Saturday, to people walking up Snowdon at the end of this month, one person has sold off their vinyl collection, others are making T-shirts and hoodies with the Georgys Fight logo, theres a big raffle and Georgys Fight jewellery being made and sold by another fundraiser.

A Facebook Page set up by a family friend, called Georgys Fight, lists how you can help.

Helen said that she and husband, Richard, cant thank people enough.

Georgy is undergoing his last round of chemotherapy this week.

Speaking earlier this week, Helen said: He finishes his radiotherapy this Friday (August 7) so hes struggling a bit now. Hes been having lots of nosebleeds and hes got an ulcer right at the back of his throat so hes still unable to eat much and hes got ulcers all on the left hand side of his cheek which are stinging.

They did tell us that this would happen and we expected it a bit earlier, so hes done really well to get this far but the last week or so started to take its toll.

Hes got four more sessions after this and its finished.

Did you know we offer a free email newsletter service?

Each CheshireLive bulletin delivers the latest breaking news, what's on events and the hottest talking points straight to your inbox. For more information about how - and why - to subscribe,click here.

He didnt want to go this morning because he knows that at each session its going to hurt even more, but he always bounces back. Once hes finished the radiotherapy, give him a couple of weeks and hell be back to feeling ok again I think.

Georgy has been accepted by a clinic in Thailand to undergo the vital stem cell treatment he needs next month but it is essential the treatment starts in September ensure the cancer doesnt return straight away,

That is why the family set up the JustGiving fundraising page to help save our sons life.

Read the original here:

Nearly 70K donated so far towards Wistaston boy's 120K lifesaving treatment - Cheshire Live

Coronavirus Drug and Treatment Tracker – The New York Times

The Covid-19 pandemic is one of the greatest challenges modern medicine has ever faced. Doctors and scientists are scrambling to find treatments and drugs that can save the lives of infected people and perhaps even prevent them from getting sick in the first place.

Below is an updated list of 20 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that theyre effective, most are still at early stages of research. We also included a warning about a few that are just bunk.

We are following 20 coronavirus treatments for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

There is no cure yet for Covid-19. And even the most promising treatments to date only help certain groups of patients and await validation from further trials. The F.D.A. has not fully licensed any treatment specifically for the coronavirus. Although it has granted emergency use authorization to some treatments, their effectiveness against Covid-19 has yet to be demonstrated in large-scale, randomized clinical trials.

This list provides a snapshot of the latest research on the coronavirus, but does not constitute medical endorsements. Always consult your doctor about treatments for Covid-19.

New additions and recent updates:

Added ivermectin, a drug typically used against parasitic worms that is being increasingly prescribed in Latin America. Aug. 10

Updated descriptions for several treatments. Aug. 10

We will update and expand the list as new evidence emerges. For details on evaluating treatments, see the N.I.H. Covid-19 Treatment Guidelines. For the current status of vaccine development, see our Coronavirus Vaccine Tracker.

WIDELY USED: These treatments have been used widely by doctors and nurses to treat patients hospitalized for diseases that affect the respiratory system, including Covid-19.

PROMISING EVIDENCE: Early evidence from studies on patients suggests effectiveness, but more research is needed. This category includes treatments that have shown improvements in morbidity, mortality and recovery in at least one randomized controlled trial, in which some people get a treatment and others get a placebo.

TENTATIVE OR MIXED EVIDENCE: Some treatments show promising results in cells or animals, which need to be confirmed in people. Others have yielded encouraging results in retrospective studies in humans, which look at existing datasets rather than starting a new trial. Some treatments have produced different results in different experiments, raising the need for larger, more rigorously designed studies to clear up the confusion.

NOT PROMISING: Early evidence suggests that these treatments do not work.

PSEUDOSCIENCE OR FRAUD: These are not treatments that researchers have ever considered using for Covid-19. Experts have warned against trying them, because they do not help against the disease and can instead be dangerous. Some people have even been arrested for their false promises of a Covid-19 cure.

EVIDENCE IN CELLS, ANIMALS or HUMANS: These labels indicate where the evidence for a treatment comes from. Researchers often start out with experiments on cells and then move onto animals. Many of those animal experiments often fail; if they dont, researchers may consider moving on to research on humans, such as retrospective studies or randomized clinical trials. In some cases, scientists are testing out treatments that were developed for other diseases, allowing them to move directly to human trials for Covid-19.

All treatmentsWidely usedPromisingTentative or mixedNot promisingPseudoscience

Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. Scientists are searching for antivirals that work against the new coronavirus.

PROMISING EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSEMERGENCY USE AUTHORIZATIONRemdesivirRemdesivir, made by Gilead Sciences, was the first drug to get emergency authorization from the F.D.A. for use on Covid-19. It stops viruses from replicating by inserting itself into new viral genes. Remdesivir was originally tested as an antiviral against Ebola and Hepatitis C, only to deliver lackluster results. But preliminary data from trials that began this spring suggested the drug can reduce the recovery time of people hospitalized with Covid-19 from 15 to 11 days. (The study defined recovery as either discharge from the hospital or hospitalization for infection-control purposes only.) These early results did not show any effect on mortality, though retrospective data released in July hints that the drug might reduce death rates among those who are very ill.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSFavipiravirOriginally designed to beat back influenza, favipiravir blocks a viruss ability to copy its genetic material. A small study in March indicated the drug might help purge the coronavirus from the airway, but results from larger, well-designed clinical trials are still pending.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMK-4482Another antiviral originally designed to fight the flu, MK-4482 (previously known as EIDD-2801) has had promising results against the new coronavirus in studies in cells and on animals. Merck, which has been running clinical trials on the drug this summer, has announced it will launch a large Phase III trial in September.Updated Aug. 6

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS Recombinant ACE-2To enter cells, the coronavirus must first unlock them a feat it accomplishes by latching onto a human protein called ACE-2. Scientists have created artificial ACE-2 proteins which might be able to act as decoys, luring the coronavirus away from vulnerable cells. Recombinant ACE-2 proteins have shown promising results in experiments on cells, but not yet in animals or people.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS IvermectinFor decades, ivermectin has served as a potent drug to treat parasitic worms. Doctors use it against river blindness and other diseases, while veterinarians give dogs a different formulation to cure heartworm. Studies on cells have suggested ivermectin might also kill viruses. But scientists have yet to find evidence in animal studies or human trials that it can treat viral diseases. As a result, Ivermectin is not approved to use as an antiviral.

In April, Australian researchers reported that the drug blocked coronaviruses in cell cultures, but they used a dosage that was so high it might have dangerous side effects in people. The FDA immediately issued a warning against taking pet medications to treat or prevent Covid-19. These animal drugs can cause serious harm in people, the agency warned.

Since then a number of clinical trials have been launched to see if a safe dose of ivermectin can fight Covid-19. In Singapore, for example, the National University Hospital is running a 5,000-person trial to see if it can prevent people from getting infected. As of now, theres no firm evidence that it works. Nevertheless ivermectin is being prescribed increasingly often in Latin America, much to the distress of disease experts.Updated Aug. 10

NOT PROMISING EVIDENCE IN CELLS AND HUMANS Lopinavir and ritonavirTwenty years ago, the F.D.A. approved this combination of drugs to treat H.I.V. Recently, researchers tried them out on the new coronavirus and found that they stopped the virus from replicating. But clinical trials in patients proved disappointing. In early July, the World Health Organization suspended trials on patients hospitalized for Covid-19. They didnt rule out studies to see if the drugs could help patients not sick enough to be hospitalized, or to prevent people exposed to the new coronavirus from falling ill. The drug could also still have a role to play in certain combination treatments.

NOT PROMISING EVIDENCE IN CELLS, ANIMALS AND HUMANSHydroxychloroquine and chloroquineGerman chemists synthesized chloroquine in the 1930s as a drug against malaria. A less toxic version, called hydroxychloroquine, was invented in 1946, and later was approved for other diseases such as lupus and rheumatoid arthritis. At the start of the Covid-19 pandemic, researchers discovered that both drugs could stop the coronavirus from replicating in cells.

Since then, theyve had a tumultuous ride. A few small studies on patients offered some hope that hydroxychloroquine could treat Covid-19. The World Health Organization launched a randomized clinical trial in March to see if it was indeed safe and effective for Covid-19, as did Novartis and a number of universities. Meanwhile, President Trump repeatedly promoted hydroxychloroquine at press conferences, touting it as a game changer, and even took it himself. The F.D.A. temporarily granted hydroxychloroquine emergency authorization for use in Covid-19 patients which a whistleblower later claimed was the result of political pressure. In the wake of the drugs newfound publicity, demand spiked, resulting in shortages for people who rely on hydroxychloroquine as a treatment for other diseases.

But more detailed studies proved disappointing. A study on monkeys found that hydroxychloroquine didnt prevent the animals from getting infected and didnt clear the virus once they got sick. Randomized clinical trials found that hydroxychloroquine didnt help people with Covid-19 get better or prevent healthy people from contracting the coronavirus. Another randomized clinical trial found that giving hydroxychloroquine to people right after being diagnosed with Covid-19 didnt reduce the severity of their disease. (One large-scale study that concluded the drug was harmful as well was later retracted.) The World Health Organization, the National Institutes of Health and Novartis have since halted trials investigating hydroxychloroquine as a treatment for Covid-19, and the F.D.A. revoked its emergency approval. The F.D.A. now warns that the drug can cause a host of serious side effects to the heart and other organs when used to treat Covid-19.

In July, researchers at Henry Ford hospital in Detroit published a study finding that hydroxychloroquine was associated with a reduction in mortality in Covid-19 patients. President Trump praised the study on Twitter, but experts raised doubts about it. The study was not a randomized controlled trial, in which some people got a placebo instead of hydroxychloroquine. The studys results might not be due to the drug killing the virus. Instead, doctors may have given the drug to people who were less sick, and thus more likely to recover anyway.

Despite negative results, a number of hydroxychloroquine trials have continued, although most are small, testing a few dozen or a few hundred patients. A recent analysis by STAT and Applied XL found more than 180 ongoing clinical trials testing hydroxychloroquine or chloroquine, for treating or preventing Covid-19. Although its clear the drugs are no panacea, its theoretically possible they could provide some benefit in combination with other treatments, or when given in early stages of the disease. Only well-designed trials can determine if thats the case.Updated Aug. 10

Most people who get Covid-19 successfully fight off the virus with a strong immune response. Drugs might help people who cant mount an adequate defense.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS Convalescent plasmaA century ago, doctors filtered plasma from the blood of recovered flu patients. So-called convalescent plasma, rich with antibodies, helped people sick with flu fight their illness. Now researchers are trying out this strategy on Covid-19. In May, the F.D.A. designated convalescent plasma an investigational product. That means that despite not yet being shown as safe and effective, plasma can be used in clinical trials and given to some patients who are seriously ill with Covid-19. Tens of thousands of patients in the U.S. have received plasma through a program launched by the Mayo Clinic and the federal government.

The Trump administration has praised convalescent plasma, despite the lack of evidence yet that it works. The first wave of trials have been small and the results have been mixed. Large randomized clinical trials are underway, but theyve struggled to enroll enough participants, some of whom worry they will receive a placebo instead of the treatment itself.

Experts say that its vital to complete these trials to determine if convalescent plasma is safe and effective. If these trials are successful, it could serve as an important stopgap measure until more potent therapies become widely available.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMonoclonal antibodiesConvalescent plasma from people who recover from Covid-19 contains a mix of different antibodies. Some of the molecules can attack the coronavirus, but many are directed at other pathogens. Researchers have sifted through this slurry to find the most potent antibodies against Covid-19. They have then manufactured synthetic copies of these molecules, known as monoclonal antibodies. Researchers have begun investigating them as a treatment for Covid-19, either individually or in cocktails.

Monoclonal antibodies were first developed as a therapy in the 1970s, and since then the F.D.A. has approved them for 79 diseases, ranging from cancer to AIDS. Since the start of the pandemic, researchers have found dozens of monoclonal antibodies that show promise against Covid-19 in preclinical studies on cells and animals. Companies like Eli Lilly and Regeneron recently began clinical trials studying monoclonal antibodies. Several other firms, as well as teams at universities, are slated to enter the race soon as well.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSInterferonsInterferons are molecules our cells naturally produce in response to viruses. They have profound effects on the immune system, rousing it to attack the invaders, while also reining it in to avoid damaging the bodys own tissues. Injecting synthetic interferons is now a standard treatment for a number of immune disorders. Rebif, for example, is prescribed for multiple sclerosis.

As part of its strategy to attack our bodies, the coronavirus appears to tamp down interferon. That finding has encouraged researchers to see whether a boost of interferon might help people weather Covid-19, particularly early in infection. Early studies, including experiments in cells and mice, have yielded encouraging results that have led to clinical trials.

An open-label study in China suggested that the molecules could help prevent healthy people from getting infected. On July 20, the British pharmaceutical company Synairgen announced that an inhaled form of interferon called SNG001 lowered the risk of severe Covid-19 in infected patients in a small clinical trial. The full data have not yet been released to the public, or published in a scientific journal. On August 6, the National Institute of Allergy and Infectious Diseases launched a Phase III trial on a combination of Rebif and the antiviral remdesivir, with results expected by fall 2020.Updated Aug. 10

The most severe symptoms of Covid-19 are the result of the immune systems overreaction to the virus. Scientists are testing drugs that can rein in its attack.

PROMISING EVIDENCE EVIDENCE IN HUMANS DexamethasoneThis cheap and widely available steroid blunts many types of immune responses. Doctors have long used it to treat allergies, asthma and inflammation. In June, it became the first drug shown to reduce Covid-19 deaths. That study of more than 6,000 people, which in July was published in the New England Journal of Medicine, found that dexamethasone reduced deaths by one-third in patients on ventilators, and by one-fifth in patients on oxygen. It may be less likely to help and may even harm patients who are at an earlier stage of Covid-19 infections, however. In its Covid-19 treatment guidelines, the National Institutes of Health recommends only using dexamethasone in patients with COVID-19 who are on a ventilator or are receiving supplemental oxygen.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Cytokine InhibitorsThe body produces signaling molecules called cytokines to fight off diseases. But manufactured in excess, cytokines can trigger the immune system to wildly overreact to infections, in a process sometimes called a cytokine storm. Researchers have created a number of drugs to halt cytokine storms, and they have proven effective against arthritis and other inflammatory disorders. Some turn off the supply of molecules that launch the production of the cytokines themselves. Others block the receptors on immune cells to which cytokines would normally bind. A few block the cellular messages they send. Depending on how the drugs are formulated, they can block one cytokine at a time, or muffle signals from several at once.

Against the coronavirus, several of these drugs have offered modest help in some trials, but faltered in others. Drug companies Regeneron and Roche drug both recently announced that two drugs called sarilumab and tocilizumab, which both target the cytokine IL-6, did not appear to benefit patients in Phase 3 clinical trials. Many other trials remain underway, several of which combine cytokine inhibitors with other treatments.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS EMERGENCY USE AUTHORIZATIONBlood filtration systemsThe F.D.A. has granted emergency use authorization to several devices that filter cytokines from the blood in an attempt to cool cytokine storms. One machine, called Cytosorb, can reportedly purify a patients entire blood supply about 70 times in a 24-hour period. A small study in March suggested that Cytosorb had helped dozens of severely ill Covid-19 patients in Europe and China, but it was not a randomized clinical trial that could conclusively demonstrate it was effective. A number of studies on blood filtration systems are underway, but experts caution that these devices carry some risks. For example, such filters could remove beneficial components of blood as well, such as vitamins or medications.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Stem cellsCertain kinds of stem cells can secrete anti-inflammatory molecules. Over the years, researchers have tried to use them as a treatment for cytokine storms, and now dozens of clinical trials are under way to see if they can help patients with Covid-19. But these stem cell treatments havent worked well in the past, and its not clear yet if theyll work against the coronavirus.

Doctors and nurses often administer other supportive treatments to help patients with Covid-19.

WIDELY USEDProne positioningThe simple act of flipping Covid-19 patients onto their bellies opens up the lungs. The maneuver has become commonplace in hospitals around the world since the start of the pandemic. It might help some individuals avoid the need for ventilators entirely. The treatments benefits continue to be tested in a range of clinical trials.

WIDELY USEDEMERGENCY USE AUTHORIZATIONVentilators and other respiratory support devicesDevices that help people breathe are an essential tool in the fight against deadly respiratory illnesses. Some patients do well if they get an extra supply of oxygen through the nose or via a mask connected to an oxygen machine. Patients in severe respiratory distress may need to have a ventilator breathe for them until their lungs heal. Doctors are divided about how long to treat patients with noninvasive oxygen before deciding whether or not they need a ventilator. Not all Covid-19 patients who go on ventilators survive, but the devices are thought to be lifesaving in many cases.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS AnticoagulantsThe coronavirus can invade cells in the lining of blood vessels, leading to tiny clots that can cause strokes and other serious harm. Anticoagulants are commonly used for other conditions, such as heart disease, to slow the formation of clots, and doctors sometimes use them on patients with Covid-19 who have clots. Many clinical trials teasing out this relationship are now underway. Some of these trials are looking at whether giving anticoagulants before any sign of clotting is beneficial.

False claims about Covid-19 cures abound. The F.D.A. maintains a list of more than 80 fraudulent Covid-19 products, and the W.H.O. debunks many myths about the disease.

WARNING: DO NOT DO THISDrinking or injecting bleach and disinfectantsIn April, President Trump suggested that disinfectants such as alcohol or bleach might be effective against the coronavirus if directly injected into the body. His comments were immediately refuted by health professionals and researchers around the world as well as the makers of Lysol and Clorox. Ingesting disinfectant would not only be ineffective against the virus, but also hazardous possibly even deadly. In July, Federal prosecutors charged four Florida men with marketing bleach as a cure for COVID-19.

WARNING: NO EVIDENCEUV lightPresident Trump also speculated about hitting the body with ultraviolet or just very powerful light. Researchers have used UV light to sterilize surfaces, including killing viruses, in carefully managed laboratories. But UV light would not be able to purge the virus from within a sick persons body. This kind of radiation can also damage the skin. Most skin cancers are a result of exposure to the UV rays naturally present in sunlight.

WARNING: NO EVIDENCESilverThe F.D.A. has threatened legal action against a host of people claiming silver-based products are safe and effective against Covid-19 including televangelist Jim Bakker and InfoWars host Alex Jones. Several metals do have natural antimicrobial properties. But products made from them have not been shown to prevent or treat the coronavirus.

Note: After additional discussions with experts we have adjusted several labels on the tracker. The Strong evidence label has been removed until further research identifies treatments that consistently benefit groups of patients infected by the coronavirus. In its place, Promising evidence will be used for drugs such as remdesivir and dexamethasone that have shown promise in at least one randomized controlled trial, and Widely used for treatments such as proning and ventilators that are often used with severely ill patients, including those with Covid-19. And we may reintroduce the Ineffective label when ongoing clinical trials repeatedly end with disappointing results.

Sources: National Library of Medicine; National Institutes of Health; William Amarquaye, University of South Florida; Paul Bieniasz, Rockefeller University; Jeremy Faust, Brigham & Womens Hospital; Matt Frieman, University of Maryland School of Medicine; Noah Haber, Stanford University; Swapnil Hiremath, University of Ottawa; Akiko Iwaskai, Yale University; Paul Knoepfler, University of California, Davis; Elena Massarotti, Brigham and Womens Hospital; John Moore and Douglas Nixon, Weill Cornell Medical College; Erica Ollman Saphire, La Jolla Institute for Immunology; Regina Rabinovich, Harvard T.H. Chan School of Public Health; Ilan Schwartz, University of Alberta; Phyllis Tien, University of California, San Francisco.

More:

Coronavirus Drug and Treatment Tracker - The New York Times

World of technology changed forever by the pandemic – TechTarget

jamesteohart/stock.adobe.com

We'll never see a year like 2020 again. Let's hope not, anyway.

We're barely halfway through the year, but it's been chock-full with once-in-a-lifetime or even once-in-a-generation events. We've experienced a pandemic, a major recession, street protests and the occasional riot in major cities around the world.

We've seen major sports seasons interrupted or delayed, only to resume without fans in the stands. Unemployment has spiked to levels of the Great Depression. The U.S. presidential election includes virtual conventions, social-distanced debates and uncertainty as to how ballots will be cast.

The world of technology has changed, too. Working at home is the norm, and we've seen cloud use spiking, buying patterns disrupted and face-to-face communication becoming rare.

Sports fans, economists and political junkies will probably never see another year like this, and they can't wait for life to get back to normal. But for the IT world, many changes will become the new normal.

Some modifications accelerated yearslong trends: a move to the cloud, smaller data center footprints, buying infrastructure as a utility or a service, and a greater emphasis on security and software. But the most sudden change is of a personal nature -- the way we interact. Besides prompting most meetings with co-workers to go virtual, the pandemic changed the way storage and other IT customers interact with vendors.

Call it software-defined sales, where Zoom, Microsoft Teams, Slack and streaming virtual events replace face-to-face on-site meetings and physical user conferences. Fast-tracked due to COVID-19, virtual interactions are the new norm and will only become more so in the coming years.

Gartner predictedthat only 25% of work meetings will take place in person by 2024, down from 60% at the start of 2020.

"We do not see this shift as temporary. In fact, we see the future of work changing permanently," said Nutanix CEO Dheeraj Pandey.

Pandey said the hyper-converged infrastructure vendor experienced no drop-off in lead generation after the first few months of remote work and virtual communications with users due to the new coronavirus. Other storage vendor executives agreed. While business may have suffered because of economic conditions, there has been no lack of interaction internally or between sellers and customers.

"I am remote, yet more connected than ever with a deeper sense of unity," Dell Technologies COO Jeff Clarke said during his company's first post-pandemic earnings call in May. "I'm not traveling, but I'm visiting with more customers, partners, suppliers and team members. And I'm busier than ever."

Pure Storage CEO Charlie Giancarlo said he talks to twice as many customers as he used to while working from home, and his sales team has been more productive.

"So, if anything, I expect that we're going to see sales in a B2B environment permanently take on more of a virtual digital technique," he said on Pure's May earnings call.

We're still not sure what the future holds for in-person industry and vendor events. March and April were filled with decisions to shift vendor conferences to virtual shows. There was a spate of virtual conferences in May and June, while others moved to September and October. Going virtual deprives storage buyers of face-to-face meetings with peers and vendors, hands-on training and roadmap sessions.

We do not see this shift as temporary. In fact, we see the future of work changing permanently. Dheeraj PandeyCEO, Nutanix

However, more people can tune in without having to jump on an airplane and take time away from their day-to-day duties. Expect vendors to continue to tailor shows just as much to virtual attendees even as they ramp up conferences again in the real world.

Many found early virtual conferences had the feel of webinars more than events. Companies that have delayed their virtual shows until later in 2020 -- such as Dell and Nutanix -- have additional time to prepare and, hopefully, come up with more creative ideas.

"Overnight, we can make this a global event, instead of [a regional] event," Pandey said of the virtual .NEXT conference. "We can stream this to anywhere and everywhere. We're thinking real hard about being creative. Virtual doesn't mean copying what you did in the physical world."

Pandey said he didn't want to "spill the beans" about how creative Nutanix will get, but he gave some hints. He wants the show to have short, broadcast-quality sessions like Quibi or TikTok.

"It has to be engaging," he said. "You can stream it to people who don't want to fly to a physical event. You can get people [to watch] for five minutes, [so] it makes for a good break."

As for whether .NEXT and other conferences will go back to being physical events, Pandey said: "It's like public versus private cloud, onshoring versus offshoring. We know the pendulum has to come to rest in the middle."

The IT world pendulum will never swing back to the "old normal" of the pre-2020 world.

View post:

World of technology changed forever by the pandemic - TechTarget